Skip to content
Dr Lal Pathlabs logo

Dr Lal Pathlabs

LALPATHLAB NSE
₹2,006.00 +42.80 (+2.18%)
Market Cap
₹33,670 Cr
P/E
57.48
View as Markdown
MCP
Close 20 Nov 2026 ₹2,006.00 1Y +445.45 +28.5%
Start ₹1,560.55

Key Fundamentals

SmallcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
28.00%
Debt to Equity
0.08
EPS (TTM)
₹34.90
Book Value
₹163.54
Market Cap
₹33,670 Cr
P/E (TTM)
57.48
P/B
12.27
ROE
22.30%
Dividend Yield
0.51%
EBITDA
₹884 Cr
52W High
₹2,079.00
52W Low
₹1,272.60
Day Range
₹1,940.00 – ₹2,028.20
Volume
2,64,951

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Dr Lal Pathlabs peer comparison
Dr Lal Pathlabs (this company)
2,006.0057.4833,67012.270.51%22.30%28.00%3,034587
1,572.3079.4516,19415.320.13%18.90%20.50%911203
566.0052.3111,7387.150.18%13.60%17.80%1,778225
528.4558.338,41115.212.78%28.40%35.40%930143
655.8051.396,5955.550.00%8.83%15.30%1,110128
519.0516.671,6841.600.39%10.90%12.70%783100
311.5038.791,6225.880.14%14.20%17.30%34641
Median 7 companies566.0052.318,4117.150.18%14.20%17.80%930143

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

53 Average

Data confidence 100/100

Category scores

Quality
66
Strong
Returns, margins, earnings quality 22% weight
Valuation
51
Average
Cheap vs sector & own history 24% weight
Growth
48
Average
Sales & profit trajectory 9% weight
Financial Health
81
Strong
Solvency, leverage, coverage 9% weight
Momentum
46
Average
Trend strength, vol-adjusted 12% weight
Ownership
44
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 36.4%

Weaknesses

2
  • Stock is trading at 12.3 times its book value
  • The company has delivered a poor sales growth of 11.8% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2611
OscillatorsBearish261
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
57.81
Neutral
MACD (12,26,9)
20.37
Bearish
SMA (50)
1,936.16
Bullish
SMA (200)
1,680.96
Bullish

As of

Analyst Rating

Based on 25 analysts
BUY68%

17 of 25 analysts rate Buy, 4 Hold, 4 Sell.

As of

BUY
17
68%
HOLD
4
16%
SELL
4
16%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+13.32%
5Y+11.81%
3Y+11.06%
1Y+12.27%
TTM+16.69%

Net profit

Net profit growth by window
10Y+14.39%
5Y+11.50%
3Y+28.39%
1Y+3.66%
TTM+8.70%

Operating cash flow

Operating cash flow growth by window
10Y+14.87%
5Y+9.83%
3Y+11.73%
1Y+11.78%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+1.79 pp
5Y+0.76 pp
3Y+4.05 pp
1Y−0.02 pp
TTM+1.05 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹912 Cr
Mar 2018₹1,057 Cr
Mar 2019₹1,203 Cr
Mar 2020₹1,330 Cr
Mar 2021₹1,581 Cr
Mar 2022₹2,087 Cr
Mar 2023₹2,017 Cr
Mar 2024₹2,227 Cr
Mar 2025₹2,461 Cr
Mar 2026₹2,763 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹156 Cr
Mar 2018₹172 Cr
Mar 2019₹200 Cr
Mar 2020₹228 Cr
Mar 2021₹296 Cr
Mar 2022₹350 Cr
Mar 2023₹241 Cr
Mar 2024₹362 Cr
Mar 2025₹492 Cr
Mar 2026₹510 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹225 Cr −28.4% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 16 Nov 2026
AI opinion · based on fundamentals
Risk medium

As of 2026-11-16, Dr Lal PathLabs Ltd trades at ₹2,000.70 with a market cap of ₹33,581.51 crore and a PE (TTM) of 57.33. The company is nearly debt-free with a debt-to-equity ratio of 0.08 and maintains a consistent ROE of around 22% over the past decade, though revenue growth has been modest at 11% CAGR over three years and the stock trades at 12.24 times book value.

Bull Case 8
  • The company is virtually debt-free with a debt-to-equity ratio of just 0.08, providing significant financial flexibility and resilience through economic cycles.
  • Return on equity has remained consistently strong at 22% over 3-year, 5-year, and 10-year periods, indicating durable capital efficiency and a wide economic moat in diagnostics.
  • Return on capital employed stands at 25.67%, reflecting disciplined capital allocation and strong underlying profitability of the asset-light diagnostics model.
  • TTM revenue growth has accelerated to 17%, meaningfully above the 3-year compounded sales growth of 11% and the 5-year rate of 12%, suggesting improving business momentum.
  • Compounded profit growth over 3 years stands at 30%, significantly outpacing the 3-year sales CAGR of 11%, pointing to operating leverage and margin expansion.
  • The stock has delivered a 1-year return of 28%, rising from a 52-week low of ₹1,272.60 to ₹2,000.70, reflecting renewed investor confidence in the growth trajectory.
  • The company maintains a healthy dividend payout ratio of 36.4% with a current yield of 0.5%, demonstrating shareholder-friendly capital return alongside reinvestment for growth.
  • 10-year compounded profit growth of 15% and sales growth of 13% demonstrate the company's ability to sustain long-term earnings expansion across market cycles.
Bear Case 7
  • Price-to-book ratio of 12.24 times is elevated, meaning investors are paying a significant premium over the company's net asset value for expected future earnings.
  • Five-year compounded sales growth of only 12% is modest for a stock commanding a 57x earnings multiple, raising questions about whether the valuation is justified by the growth rate.
  • The 5-year stock CAGR of just 2% indicates prolonged periods of poor price returns despite underlying business growth, suggesting the market periodically reprices the premium downward.
  • TTM profit growth of 13% has decelerated sharply from the 3-year compounded rate of 30%, which may signal that the margin expansion phase is normalising.
  • The dividend yield of 0.5% offers minimal income return relative to risk-free alternatives, making the stock largely dependent on capital appreciation for total returns.
  • At ₹2,000.70, the stock is trading near its 52-week high of ₹2,079, leaving only about 3.9% headroom before the recent ceiling and raising the risk of near-term mean reversion.
  • Five-year ROE averaged 21%, slightly below the 10-year average of 22%, suggesting return on equity has plateaued rather than expanded despite scale gains.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

21h ago

TL;DR: Dr Lal PathLabs delivered its strongest quarterly growth in five years with 19.6% revenue growth and 27.5% profit expansion in Q2FY27, supported by healthy 9% patient volume gains and margin improvement to 32.1%. Management's high-teens revenue growth guidance for FY27 signals continued momentum. No material headwinds emerged this cycle. The trend is clearly improving, and sustained volume growth alongside CGHS price tailwinds positions the company well heading into H2FY27.

Positives 4
  • Strong Q2 revenue up 19.6% Nov 10

    Revenue grew 19.6% YoY to ₹874 crore in Q2FY27, the highest quarterly growth in five years. Patient volumes rose 9% YoY, driving operational leverage.

  • Net profit jumps 27.5% YoY Nov 10

    Net profit rose 27.5% YoY to ₹194 crore with EBITDA margin expanding to 32.1%, reflecting improved realisations and cost efficiency.

  • High-teens revenue growth guided Nov 10

    Management guided for high-teens revenue growth for FY27, with CGHS price hikes expected to contribute 2-3% additionally.

Neutral 2
  • Shareholder vote for new director Nov 12

    Postal ballot issued for appointment of Vasuta Agarwal as Independent Director, with e-voting open from November 14 to December 13, 2026.

  • Investor conferences in Mumbai Nov 11

    Dr. Lal PathLabs will participate in investor conferences in Mumbai on November 16 and 17, 2026.

Quarterly Results

₹ Cr
LALPATHLAB quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
601
539
545
602
660
597
603
670
731
660
703
798
874
Expenses
424
398
401
432
458
443
434
478
506
480
516
550
594
Operating Profit
178
141
145
170
202
154
169
192
224
179
187
248
280
OPM %
30%
26%
27%
28%
31%
26%
28%
29%
31%
27%
27%
31%
32%
Other Income
18
18
18
21
22
25
26
28
25
24.4
24
32
34.3
Interest
8
7
7
6
6
5
5
5
5
7
6
6
7
Depreciation
36
36
37
35
35
36
36
35
40
42
45
44
46.9
Exceptional Items
—
—
—
—
—
—
—
—
—
−30.1
—
—
—
PBT
152
116
120
150
183
138
153
181
204
124
160
229
261
Tax %
27%
29%
28%
28%
29%
29%
−1%
26%
25%
26%
17%
25%
26%
Net Profit
111
82
86
108
131
98
156
134
152
91
132
170
194
EPS (₹)
6.55
4.87
5.06
6.37
7.73
5.78
9.26
7.90
8.99
5.40
7.84
10.11
11.55
YoY Sales growth
13
10
11
11
10
11
10
11
11
11
17
19
20

Profit & Loss

₹ Cr
LALPATHLAB profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
660
791
912
1,057
1,203
1,330
1,581
2,087
2,017
2,227
2,461
2,763
3,034
Expenses
504
582
675
793
910
987
1,145
1,526
1,527
1,617
1,764
1,979
2,140
Operating Profit
156
210
238
264
294
344
436
561
490
609
698
783
894
OPM %
24%
26%
26%
25%
24%
26%
28%
27%
24%
27%
28%
28%
29%
Other Income
12
20
27
31
46
55
51
52
42
69
91
70
84
Interest
0
0
1
1
1
15
16
30
38
29
22
23
27
Depreciation
28
28
28
33
38
73
77
108
150
144
142
162
178
PBT
140
201
237
261
301
310
394
475
344
505
625
669
774
Tax %
31%
34%
34%
34%
33%
27%
25%
26%
30%
28%
21%
24%
—
Net Profit
96
133
156
172
200
228
296
350
241
362
492
510
588
EPS (₹)
8.75
7.99
9.31
10.24
11.95
13.55
17.49
20.69
14.33
21.42
29.14
30.13
34.90
Div. Payout %
9%
15%
16%
22%
25%
44%
57%
29%
42%
0%
41%
68%
—
Sales growth
18
20
15
16
14
11
19
32
−3
10
11
12
17

Balance Sheet

₹ Cr
LALPATHLAB balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
55
83
83
83
83
83
83
83
83
83
84
168
168
Reserves
260
425
512
705
862
949
1,162
1,418
1,583
1,766
2,089
2,341
2,577
Borrowings
27
0
0
0
0
0
150
533
420
247
157
199
233
Other Liabilities
134
118
95
128
145
341
265
309
297
357
383
433
480
Total Liabilities
475
625
690
916
1,091
1,374
1,661
2,343
2,383
2,454
2,713
3,140
3,458
Fixed Assets
150
166
152
208
209
413
447
1,369
1,305
1,228
1,168
1,256
1,310
CWIP
1
4
18
10
3
11
10
15
5
6
3
7
5
Investments
38
64
106
145
185
164
59
65
150
114
327
423
530
Other Assets
286
391
414
554
694
786
1,144
893
923
1,107
1,215
1,454
1,612
Total Assets
475
625
690
916
1,091
1,374
1,661
2,343
2,383
2,454
2,713
3,140
3,458

Cash Flow

₹ Cr
LALPATHLAB cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
122
159
171
197
219
284
398
447
456
535
569
636
Investing
−113
−163
−137
−172
−100
−26
−212
−449
−287
−24
−303
−422
Financing
−1
0
−32
13
−55
−190
−139
136
−283
−414
−334
−264
Net Cash Flow
8
−5
2
37
64
67
48
134
−114
97
−68
−50
Free Cash Flow
87
115
120
125
177
205
339
−28
412
479
516
463
CFO/EBITDA
112
108
102
110
110
110
115
103
115
110
105
104

Ratios

LALPATHLAB financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
17
17
17
14
16
14
15
15
13
13
13
15
Inventory Days
37
31
33
44
40
70
39
38
28
30
27
30
Days Payable
90
89
97
106
111
144
132
107
127
151
127
123
Cash Conversion Cycle
−35
−42
−47
−47
−55
−60
−78
−54
−87
−108
−86
−79
Working Capital Days
−9
27
19
17
0
−19
−26
−54
−56
−46
−30
−29
ROCE %
48%
47%
43%
38%
35%
32%
33%
29%
18%
25%
29%
28%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dr Lal Pathlabs insights

66 extracted metrics across FY14–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.93%
  • DIIs 21.58%
  • FIIs 18.73%
  • Public 5.30%
  • Others 1.46%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Dr Lal Pathlabs

What does Dr Lal Pathlabs Ltd do?
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient…
Where is Dr Lal Pathlabs Ltd (LALPATHLAB) listed?
Dr Lal Pathlabs Ltd trades as LALPATHLAB on the NSE and under code 539524 on the BSE.
Which sector does Dr Lal Pathlabs Ltd belong to?
Dr Lal Pathlabs Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd has a market capitalisation of ₹33,670 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd trades at a PE ratio of 57.48 as of 20 Nov 2026, on earnings per share of ₹34.9, against a book value of ₹163.54 per share.
What is the 52-week high and low of Dr Lal Pathlabs Ltd?
Over the last 52 weeks Dr Lal Pathlabs Ltd has traded between ₹1,272.6 and ₹2,079 as of 20 Nov 2026.
Does Dr Lal Pathlabs Ltd pay dividends?
Dr Lal Pathlabs Ltd has a dividend yield of 0.51%.
What is the Return on Equity (ROE) of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd reported a return on equity of 22.30%. Its debt-to-equity ratio is 0.08.

Company Information

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.

Listed 23 Dec 2015
Face Value ₹10
Shares Outstanding 16,78,48,820

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LALPATHLAB.md for Dr Lal Pathlabs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More